Aaron's delivered adjusted earnings of 79 cents per share, which surpassed the Zacks Consensus Estimate of 78 cents. The bottom line also advanced 11.3% from 71 cents earned in the prior-year quarter.
Not sure why some are reporting a missed estimate on this chat
Can SAVA sustain $2B valuation, even with a Phase 3 continuation? What data are they providing to show anything , except that they had “successful” FDA meeting? There is no drug pipeline, might be too early peaked out on their value prop. Look at G1TX, they got FDA approval for their drug, still half SAVA price. Believing in something is good but do DD too.
Medical space doesn’t work on quick tweets. If data isn’t supportive, studies are halted immediately. This is highly regulated field.
Here is more strength to why $AVXL has potential- http://tiny.cc/u5pltz
They are en route to find partner for IND submission, once find a partner who can promote and sell their covid nasal spray.
Some more interesting stuff around their ongoing tests under COVID-19
https://finance.yahoo.com/news/atossa-therapeutics-president-ceo-dr-143000932.html
Coming from the CEO at $ATOS -
During 2020, we completed successful in-vitro testing followed by a Phase 1 clinical study with preliminary data demonstrating safety and tolerability. We recently received written feedback from the FDA from a pre-IND meeting that is informing our clinical and regulatory strategy. We expect to release final data from this study in the first quarter of 2021 and then quickly start additional pre-clinical and clinical studies to support an investigational new drug application (IND) with the FDA.
Over 8M volume transacted at market open!
8M bought at market open?